The Singular method begins by measuring before formulating. Its panel includes 25-OH-D, ferritin, serum magnesium, vitamin B12, and hs-CRP among other markers, then cross-reads those results with the member's profile. This selection serves a specific formulation engine; it does not mean that five tests identify every adult's needs or should be prescribed universally. Trials of standardized supplementation in unselected populations mainly show that an identical dose does not guarantee an average benefit.
The biomarker-first approach inverts the prevailing commercial logic. It does not start from a product looking for a target population. It starts from an individual biological profile and deduces the appropriate formula.
Why blind supplementation fails
The first myth to dismantle is that of universal benefit. Supplementing an entire population with a given nutrient can produce a disappointing average result. The VITAL trial, conducted on 25,871 American adults with 2,000 IU of vitamin D3 daily for more than five years, showed no significant reduction in major cardiovascular events or invasive cancers compared with placebo (PubMed). This result defines no serum target and does not prove that a strategy titrated to 25-OH-D would have improved those endpoints.
Vitamin E tells a darker story. The SELECT trial followed 35,533 healthy men on 400 IU of vitamin E daily. The supplemented group showed a significant increase in prostate cancer risk compared with placebo (PubMed). Giving a supraphysiological antioxidant dose to a population without documented deficiency can cause harm.
An older meta-analysis of vitamin D and total mortality, covering 18 randomized trials and 57,311 participants, reported a modest average effect (RR 0.93) (PubMed). It establishes neither an optimal serum range nor a benefit confined to people below a particular threshold.
The lesson is narrower: these trials do not validate a universal dose. Baseline status can matter, but it is not enough to turn an association into a clinical benefit. This is the central idea developed in our article The Multivitamin Myth: applying the same dose to everyone ignores biological variability.
Five biomarkers in the Singular panel
The five tests below belong to the Singular panel and inform several formulation decisions. They do not replace a complete medical workup and are not a universal screening list for every adult.
1. 25-hydroxyvitamin D (25-OH-D)
Total 25(OH)D, the sum of the D2 and D3 fractions, is the principal blood marker of vitamin D status. Singular uses 20 to 50 ng/mL as its internal Optimal range: this indirect synthesis combines a broad observational plateau, nutritional anchors, and caution at high values. It is neither a consensus range nor evidence that reaching its upper end improves longevity. The nutritional anchors remain distinct: below 12 ng/mL indicates risk of deficiency, 12 to below 20 is generally inadequate, and 20 or above is generally adequate for most healthy people.
In the Singular formula, the current result guides the vitamin D3 tier through a fixed grid: no result 15 µg; x ≤ 12 70 µg; 12 < x ≤ 20 50 µg; 20 < x ≤ 30 25 µg; 30 < x ≤ 40 15 µg; x > 40 0 µg. Season and history contextualize the blood test but do not automatically modify that tier. See the detailed page Vitamin D (25-OH-D).
2. Ferritin
The primary marker of iron stores. Low ferritin (typically below 30 µg/L per WHO thresholds) indicates a nutritional iron need, even without overt anemia. A classic pitfall: ferritin is also an acute-phase protein that rises with inflammation or overweight. In people with excess body weight, normal or elevated ferritin can mask a functional iron deficit (PubMed). This is why it should always be read alongside hs-CRP.
This biomarker is critical before any intake of iron. Iron supplementation in an already overloaded individual is pro-oxidant and raises hepatic risk. See Ferritin.
3. Serum magnesium
Circulating magnesium represents only about 1% of total body magnesium; most of it sits in bone and the intracellular compartment (PubMed). Magnesemia is tightly regulated: a low serum magnesium signals an established depletion, while a normal value does not rule out early tissue depletion. This is why it is read in the upper part of the range, not merely above the reference floor.
Red blood cell magnesium, measured inside the erythrocyte, is often presented as closer to tissue stores. The only systematic review devoted to magnesium markers in fact judges serum, red blood cell and urinary excretion all three useful, with no hierarchy among them (PubMed), and few laboratories offer the erythrocyte matrix routinely. Serum magnesium, by contrast, is universally available, reproducible, and remains the only one where a high circulating concentration is read directly. In an optimization logic, where magnesium intake is often proactive, bounding the top matters as much as the bottom. The desirable zone lies between 0.85 and 0.95 mmol/L. Below that, a magnesium supplement in a bioavailable form becomes relevant. See Magnesium.
4. Vitamin B12
The standard serum B12 assay lacks sensitivity and specificity. An individual can have a "normal" serum B12 and a documented functional deficit revealed by elevated methylmalonic acid (MMA) or homocysteine (PubMed). Commonly used diagnostic thresholds underestimate needs, particularly in individuals over 50, strict vegetarians, people on metformin, or on proton pump inhibitors.
A B12 below 300 pg/mL justifies MMA testing to confirm. When deficiency is confirmed, supplementation with vitamin B12 as methylcobalamin or hydroxocobalamin raises blood markers from the first weeks, in proportion to the dose; full repletion takes longer, and a minority still shows non-normalised markers after eight weeks at 500 µg per day (PubMed). See Vitamin B12.
5. hs-CRP (high-sensitivity C-reactive protein)
hs-CRP is not a direct nutritional marker: it is the inflammatory thermostat. Its reference thresholds, established in large cardiovascular cohorts, stratify risk into three zones (below 1 mg/L: low, 1 to 3 mg/L: intermediate, above 3 mg/L: high) (PubMed). An elevated hs-CRP radically changes the interpretation of other markers (ferritin and B12 in particular) and points toward bioactives targeting inflammatory modulation (omega-3, magnesium, polyphenols) rather than standard supplementation.
It completes the picture by locating the individual on their baseline inflammatory axis. See hs-CRP.
These five markers belong to the Singular panel and inform its formulation. They form neither a complete medical workup nor a universal screening prescription.
Reading your panel: what each value says about needs
Having the numbers is not enough. Interpretation drives the formula. Four reading angles structure the analysis.
Vertical reading. A laboratory range and an internal formulation range answer different questions. For vitamin D, Singular uses 20 to 50 ng/mL as an indirect internal target, without claiming that a value above 40 is better than one between 20 and 30. The other markers retain their own rules and interpretation limits.
Cross reading. A biomarker taken alone can mislead. A ferritin at 90 µg/L with hs-CRP at 5 mg/L likely signals inflammation masking a worse iron status than it appears. A serum B12 at 350 pg/mL with homocysteine at 14 µmol/L suggests a functional deficit despite apparent normality. It is the combination that informs, not the isolated value, as analyzed in our article on homocysteine.
Longitudinal reading. A one-off value is a snapshot, and repeated measurements describe a useful follow-up trajectory. For vitamin D, however, the engine reassesses the tier from the current result: neither the slope nor the previous dose is an automatic input.
Contextual reading. Needs vary with age, biological sex, physical activity, pregnancy, medications, and chronic conditions. An endurance athlete has above-average iron and magnesium needs. A patient on a proton pump inhibitor absorbs B12 poorly. A strict vegetarian has virtually no dietary B12 intake. A panel only makes sense within that context.
Classic supplementation pitfalls
Once the biomarkers are read, three major pitfalls remain on the product side.
Proprietary blends. Formulas labeled "proprietary blend" or "exclusive complex" hide individual doses behind a total dose. There is no way to know whether you are getting 10 mg or 500 mg of a given bioactive. That opacity disqualifies the product. Any serious formula lists every individual dose in milligrams, with the precise chemical form. This is the absolute-dose illusion analyzed in our dedicated article.
Poorly bioavailable forms. Not all forms of a given nutrient are equal. Magnesium oxide was measured at approximately 4% fractional absorption in a comparison of commercial preparations, where the organic forms do markedly better (PubMed). Ferrous sulfate often causes digestive upset where iron bisglycinate is better tolerated. Cyanocobalamin, the most widespread synthetic form, is the only B12 whose high dose has been associated with a faster decline in renal function in people whose function is already impaired (PubMed). The chemical form drives real-world efficacy.
Nutrient antagonisms. Some nutrients interfere with each other. Calcium at high doses (300 to 600 mg) reduces iron absorption by 50 to 60% when taken at the same meal (PubMed). Zinc and copper compete: prolonged zinc supplementation without copper creates an imbalance. Iron and zinc share the same intestinal transporters. The timing of intake matters as much as the doses. This subject is developed in the article on supplement interactions.
The rational sequence: measure, interpret, calibrate
Any rational supplementation follows three steps, always in this order.
Measure. Within the Singular journey, an initial blood panel includes the markers required by the engine and can be expanded according to the profile. Outside this service, test selection depends on context and any medical indication; the five markers presented here are not a universal minimum.
Interpret. Read the values in their optimal zones (not just reference zones), cross them against each other, place them in the individual context (age, sex, diet, activity, medications). This step defines real needs, ordered by priority.
Calibrate. Choose the bioactives, their forms, and their tiers according to the applicable rules. Singular offers a first follow-up blood test around three months after starting or changing a formula, then roughly every six months to reassess the whole formula.
This sequence is also what distinguishes precision supplementation from standard supplementation, as analyzed in our comparison Multivitamin vs personalized supplementation.
Conclusion: inverting the question
The common question "which supplements should I take" is poorly framed. It starts from the product, looks for a generic need, and sells a standardized dose. That is the economics of mass-market supplementation.
The rational question is different: what information is actually available about the current profile, and what decisions is the chosen method entitled to draw from it? At Singular, this involves a dedicated blood panel. It does not mean that every supplementation context requires the same five tests.
The best supplement does not exist in the abstract. It exists for a given profile, at a given moment, at a given dose. Everything else is approximation.
Frequently asked questions
References
- Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2019;380(1):33-44. (PubMed)
- Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549-1556. (PubMed)
- Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167(16):1730-1737. (PubMed)
- Khan A, Khan WM, Ayub M, et al. Ferritin Is a Marker of Inflammation rather than Iron Deficiency in Overweight and Obese People. J Obes. 2016;2016:1937320. (PubMed)
- Costello RB, Nielsen F. Interpreting magnesium status to enhance clinical care: key indicators. Curr Opin Clin Nutr Metab Care. 2017;20(6):504-511. (PubMed)
- Witkowski M, Hubert J, Mazur A. Methods of assessment of magnesium status in humans: a systematic review. Magnes Res. 2011;24(4):163-180. (PubMed)
- Stabler SP. Clinical practice. Vitamin B12 deficiency. N Engl J Med. 2013;368(2):149-160. (PubMed)
- Hill MH, Flatley JE, Barker ME, et al. A vitamin B-12 supplement of 500 microg/d for eight weeks does not normalize urinary methylmalonic acid or other biomarkers of vitamin B-12 status in elderly people with moderately poor vitamin B-12 status. J Nutr. 2013;143(2):142-147. (PubMed)
- Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973-979. (PubMed)
- Firoz M, Graber M. Bioavailability of US commercial magnesium preparations. Magnes Res. 2001;14(4):257-262. (PubMed)
- Spence JD, Yi Q, Hankey GJ. B vitamins in stroke prevention: time to reconsider. Lancet Neurol. 2017;16(9):750-760. (PubMed)
- Hallberg L, Brune M, Erlandsson M, Sandberg AS, Rossander-Hultén L. Calcium: effect of different amounts on nonheme- and heme-iron absorption in humans. Am J Clin Nutr. 1991;53(1):112-119. (PubMed)
